This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.

More Like This

Market & Industry Analysis Straight to Your Inbox

Glideslope AI

Moderna says FDA to review its flu vaccine after reversing course

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

CBS Money Watch • Feb 18, 2026 • Found on Glideslope.ai

Post hash: pz26n5z • glideslope.ai/post/pz26n5z

Sentiment

Strong Bearish • Score: -100.0

-100 (Bearish) +100 (Bullish)

Fraywire Market Portal, Breaking Metrics Newsletter, and Glideslope AI are designed for informational purposes only. The content provided across these platforms—including, but not limited to, stock and crypto watchlists, price tracking, trade tracking, sentiment analysis, and news articles—should not be construed as financial advice or research reports. Users are encouraged to conduct their own research and consult with qualified financial professionals before making any investment decisions. While we strive to ensure the accuracy, completeness, and reliability of the information provided, Fraywire, Breaking Metrics, and Glideslope AI make no guarantees or warranties regarding the content's validity. By using these platforms, you acknowledge and agree that you are solely responsible for your own investment decisions and actions. Fraywire, Breaking Metrics, and Glideslope AI shall not be held liable for any losses or damages resulting from the use of the information provided.

Get Connected

Fraywire & Glideslope AI are Breaking Metrics productions.
Contact the developer for advertising opportunities, questions, and more at roy@rmahd.com

○ Subscribe
○ Fraywire+
○ Glideslope AI
○ Blog
○ RMAHD
○ Merch!

Pulse AI Analysis

Related Insights

More Like This

In reversal, US agrees to review new Moderna flu shot

Moderna stock surges as FDA reverses course, agrees to review new flu shot

Modernaâ€™s investigational flu vaccine moves forward in FDA review

Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine

What Moderna (MRNA)'s Flu Filing Setback and 2025 Loss Mean For Its Regulatory Path

Moderna got the FDA to change its mind and review its flu vaccine after some concessions

Market & Industry Analysis Straight to Your Inbox

My Notes